DENVER, Nov. 21 /PRNewswire-FirstCall/ -- Myogen, Inc. (Nasdaq: MYOG), a
biopharmaceutical company focused on the discovery, development and
commercialization of small molecule therapeutics for the treatment of
cardiovascular disease, today announced that it will report third quarter 2003
results on Thursday, December 4, 2003, after the U.S. financial markets close.
J. William Freytag, President and CEO, and other members of Myogen's
senior management will provide a company update and discuss third quarter
results via webcast and conference call on Friday, December 5, 2003 at
9:00am ET. To access the live webcast, please log on to the company's website
at http://www.myogen.com and go to the Investor Relations section. Alternatively,
callers may participate in the conference call by dialing 800-218-0204
(domestic) or 303-262-2140 (international). Webcast and telephone replays of
the conference call will be available approximately two hours after the
completion of the call through Friday, December 12, 2003. Callers can access
the replay by dialing 800-405-2236 (domestic) or 303-590-3000 (international).
The passcode is 560675#.
About Myogen
Myogen is a biopharmaceutical company focused on the discovery,
development and commercialization of small molecule therapeutics for the
treatment of cardiovascular disorders. Myogen currently markets one product
in Europe for the treatment of acute decompensated heart failure and is
developing three product candidates for three distinct cardiovascular
indications. The Company also conducts a target and drug discovery research
program focused on the development of disease-modifying drugs for the
treatment of chronic heart failure and related cardiovascular disorders.
Please visit our website at http://www.myogen.com .
SOURCE Myogen, Inc.
 back to top
Related links:
http://www.myogen.com
CONTACT:
Derek K. Cole, Director, Investor Relations,
+1-303-464-3986, derek.cole@myogen.com, or Joseph L. Turner,
Chief Financial Officer, +1-303-464-5222, joe.turner@myogen.com,
both of Myogen, Inc.
|
